Sygnature Discovery has announced the acquisition of Canada-based contract research organisation NuChem Sciences.
The transaction expands Sygnature’s business operations into the North American market. Together, Sygnature Discovery and NuChem hope to combine the best of North American and UK operations.
Marc Lebel, President and Chairman at NuChem Sciences, said: “We are delighted to become an integral part of the Sygnature Group, allowing us to leverage our deep scientific expertise and presence across North America and Europe, to the benefit of customers and employees.”
NuChem Sciences employs over 300 staff in Montreal and Quebec City, Canada, where the company will continue to operate and drive further market expansion across North America.
Founded in 2011, the company delivers discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology.
Dr Simon Hirst, CEO at Sygnature Discovery, commented: “This acquisition represents a pivotal milestone in the Sygnature growth plan, allowing us to deliver better discovery solutions to customers around the world.”
This is the third acquisition by Sygnature over the last sixteen months, following the investment by Five Arrows in Summer 2021. Previous acquisitions were Peak Proteins in April 2022 and SB Drug Discovery in January 2023.
